Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases.

Benefits

to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton’s Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized inflammation and disease progression in Multiple Sclerosis (MS). Zenas’ earlier stage programs include ZB021, a clinical-stage, potentially best-in-class, oral, IL-17AA/AF inhibitor; ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor; and ZB014, a preclinical half-life extended anti-CD-19 and FcγRIIb monoclonal antibody.

We are seeking top talent who share our commitment to patients and have a track record of success in acquiring, developing and commercializing products across the globe. Our colleagues have an opportunity to engage in a fast-paced learning environment and experience individual and organizational success as we work towards becoming a global immunology and autoimmune disease leader, while living our values of Transparency, Relationships, Urgency, Excellence and Innovation – TRUE Innovation ! Position Summary: The National Account Director, Payer Accounts is responsible for developing and executing payer engagement strategies that support optimal coverage, access, and reimbursement for Zenas BioPharma’s innovative portfolio.

Reporting to the Executive Director, Payer Strategy, this role will lead strategic engagement with national payer organizations, Medicare and commercial health plans, pharmacy benefit managers (PBMs), and Tier 1 regional health plans to support optimal coverage and access. The National Account Director will build and manage senior-level relationships with payer decision makers, support formulary positioning and contracting discussions, and ensure payer insights inform internal access strategy. This individual will collaborate closely with cross-functional partners including Pricing Contracting, Medical Affairs, Sales, Market Access Operations, and Patient Services to ensure payer strategy is aligned with commercial execution and supports successful patient access.

The successful candidate will bring established relationships with key national and regional payer organizations and PBMs and demonstrated success negotiating coverage and access for specialty or rare disease therapies. This role offers a unique opportunity to help shape payer access strategy and establish foundational payer partnerships in preparation for upcoming product launches.

Key Responsibilities

: Develop and maintain strategic relationships with national payer organizations, Medicare and commercial health plans, pharmacy benefit managers (PBMs), and Tier 1 regional health plans. Execute payer engagement strategies designed to support favorable coverage, reimbursement pathways, and formulary positioning for Zenas therapies. Partner with the Executive Director, Payer Strategy to support payer engagement activities leading up to anticipated product launches.